Blue Jet Healthcare Reports Strong Q3 FY25 Earnings, Announces ₹40 Crore R&D Investment

Mumbai, India – January 29, 2025—Blue Jet Healthcare Limited (NSE: BLUEJET, BSE: 544009) has reported strong financial results for Q3 FY25, driven by higher revenues, operational efficiencies, and strategic investments. The company also announced a ₹40 crore investment in setting up a Research and development (R&D) facility, signaling its focus on innovation and long-term growth in the pharmaceutical sector.

Financial Highlights: Q3 FY25 Performance​

Standalone Financial Performance (₹ in Million)​

• Revenue from Operations: ₹3,183.82 million (up 91% YoY, up 53% QoQ from ₹1,667.60 million in Q3 FY24 and ₹2,082.60 million in Q2 FY25).
• Total Income: ₹3,316.23 million (up 91% YoY, up 42.9% QoQ from ₹1,735.14 million in Q3 FY24).
• EBITDA: ₹1,324.94 million (up 147.9% YoY, up 72.2% QoQ from ₹534.44 million in Q3 FY24).
• Profit Before Tax (PBT): ₹1,324.94 million (up 160.4% YoY, 72.2% QoQ).
• Net Profit: ₹989.83 million (up 208.4% YoY, up 69.6% QoQ from ₹321.08 million in Q3 FY24).
• Earnings Per Share (EPS): ₹5.71 per share (up 208.4% YoY from ₹1.85 in Q3 FY24).

For the nine months ending December 31, 2024:

• Revenue from Operations: ₹6,895.40 million (up 30.7% YoY from ₹5,276.53 million).
• Net Profit: ₹1,951.10 million (up 57.2% YoY from ₹1,241.02 million).
• Earnings Per Share (EPS): ₹12.51, compared to ₹7.15 in the same period last year.

Operational and Cost Efficiencies Driving Profitability​

• Cost of Materials Consumed: ₹1,724.40 million (up 156.6% YoY from ₹671.89 million in Q3 FY24).
• Employee Benefits Expense: ₹148.25 million (up 13.9% YoY).
• Finance Costs: ₹0.16 million (down 56.8% YoY from ₹0.37 million in Q3 FY24).
• Depreciation & Amortization Expense: ₹44.5 million (down 43.4% YoY from ₹78.55 million in Q3 FY24).
• Total Expenses: ₹1,991.29 million (up 65.8% YoY from ₹1,200.70 million in Q3 FY24).

The switch from the written-down value (WDV) depreciation method to the Straight-Line Method (SLM) reduced depreciation expenses, increasing PBT by ₹108.48 million for the nine months and ₹36.79 million for Q3 FY25.

Strategic Investment in R&D​

The Board has approved a ₹40 crore investment in establishing a dedicated Research & Development (R&D) facility aimed at:

• Enhancing API (Active Pharmaceutical Ingredients) and pharma intermediates production.
• Developing next-generation healthcare solutions.
• Strengthening market positioning through innovation.

Key Developments and Future Outlook​

1. Strong Market Demand
   • Significant revenue growth is driven by increasing demand for pharma intermediates and APIs.
   • Improved operational efficiencies, resulting in higher margins.
2. Regulatory and Compliance Strength
   • The company remains compliant with SEBI listing regulations.
   • Financial transparency was maintained with an unmodified review report from statutory auditors.
3. Sustained Profitability and Growth Strategy
   • Robust cash flow management and declining finance costs indicate low reliance on debt.
   • Investment in R&D to support long-term product innovation and expansion into global markets.

Investor Takeaways​

• Exceptional revenue and profit growth, with a 160.4% YoY increase in PBT.
• Strategic investment in R&D, reinforcing long-term growth potential.
• Debt-free expansion strategy, ensuring sustainable financial health.
• Consistent EPS growth, enhancing shareholder value.

Conclusion​

Blue Jet Healthcare is positioned for long-term success in the pharmaceutical industry with record-breaking Q3 FY25 performance, a strong order book, and a clear growth strategy. The company's ₹40 crore investment in R&D signals a commitment to innovation, further solidifying its competitive advantage in the healthcare market.
In the coming quarters, investors can expect continued strong earnings, expansion into high-margin pharma segments, and increased global market penetration.